ASX INVESTMENT VIDEOS

Four strong biotechs in 2014

SPEAKER: Stuart Roberts, Baillieu Holst
LOCATION: Sydney
DATE: May 2014

DISCLAIMER: *The views, opinions or recommendations of the presenters are solely their own and do not in any way reflect the views, opinions, recommendations, of ASX Limited ABN 98 008 624 691 and its related bodies corporate ("ASX"). Information and material presented at the seminar is for educational purposes only and does not constitute financial product advice. Investors should obtain independent advice from an Australian financial services licensee before making investment decisions. No responsibility is accepted by ASX for any loss or damage arising in any way (including due to negligence) from anyone acting or refraining from acting as a result of this information or material.*

© Copyright 2014 ASX Operations Pty Limited ABN 42 004 523 782. All rights reserved 2013.

ASX

Disclose of potential interest and disclaimer

This document has been prepared and issued by Baillieu Holst Ltd, ABN 74 006 519 393, AFS Licence No. 245421, Participant of ASX Group, Participant of NSX Ltd

Bailiieu Holst Ltd (Baillieu Holst) and/or its associates may receive commissions, calculated at normal client rates, from transactions involving securities of the companies mentioned herein and may hold interests in securities of the companies mentioned herein from time to time. Your adviser will earn a commission of up to 50% of any brokerage resulting from any transactions you may undertake as a result of this advice.

This advice is issued on the basis that:
a) in preparing the advice, Baillieu Holst did not consider whether the advice is appropriate in light of the particular investment needs, objectives and financial situation of the investor(s) or prospective investor(s); and
b) before making an investment decision on the basis of the advice contained herein, the investor(s) or prospective investor(s) need to consider whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances.

When we provide advice to you, it is based on the information you have provided to us about your personal circumstances, financial objectives and needs. If you wish to rely on our advice, it is important that you inform us of any changes to your personal investment needs, objectives and financial circumstances.

If you do not provide us with the relevant information (including updated information) regarding your investment needs, objectives and financial circumstances, our advice may be based on inaccurate information, and you will need to consider whether the advice is suitable to you given your personal investment needs, objectives and financial circumstances. Please do not hesitate to contact our offices if you need to update your information held with us. Please be assured that we keep your information strictly confidential.

No representation, warranty or undertaking is given or made in relation to the accuracy of information contained in this advice, such advice being based solely on public information which has not been verified by Baillieu Holst Ltd.

Save for any statutory liability that cannot be excluded, Baillieu Holst Ltd and its employees and agents shall not be liable (whether in negligence or otherwise) for any error or inaccuracy in, or omission from, this advice or any resulting loss suffered by the recipient or any other person.
Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgement at its original date of publication and are subject to change without notice. The price, value of and income from any of the securities or financial instruments mentioned in this report can fall as well as rise. The value of securities and financial instruments is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities or financial instruments.

Baillieu Holst Ltd assumes no obligation to update this advice or correct any inaccuracy which may become apparent after it is given.
Authors of company comments may hold shares in companies mentioned.

Stuart Roberts, Baillieu Holst, May 2014

The first rule of Life Sciences investing…



Stuart Roberts, Baillieu Holst, May 2014

Sirtex (SRX)

A$100M PA BUSINESS IN SIR-SPHERES

STRONG DATA IN LIVER CANCER

GROWING INTEREST FROM ONCOLOGISTS

US$60M TO FUND LARGE SCALE TRIALS

FIRST DATA FROM THESE TRIALS NEXT YEAR

SIRTeX | SIR-Spheres® microspheres

Stuart Roberts, Baillieu Holst, May 2014

Somnomed (SOM)

A$18.5 PA IN FY13 REVENUE FROM DENTAL SLEEP MEDICINE

INCIDENCE OF SNORING AND SLEEP APNEA IS HIGH

GROWING USER BASE

LOW COST THERAPY

Stuart Roberts, Baillieu Holst, May 2014

Prima Biomed (PRR)

DEVELOPING CVAC, A THERAPEUTIC VACCINE FOR OVARIAN CANCER

PHASE III SHOWED NO BENEFIT FOR 'ALL COMERS'…

…BUT THERE WAS STRONG PROGRESSION-FREE SURVIVAL IMPROVEMENT FOR SECOND REMISSION PATIENTS

CVAC IS NOW IN A 210-PATIENT PHASE II TRIAL IN SECOND REMISSION PATIENTS



Stuart Roberts, Baillieu Holst, May 2014

Benitec (BLT)

A PIONEER IN GENE SILENCING

LEAD PROGRAM IN HEPATITIS C

OTHER PROGRAMS IN HEPATITIS B, AGE-RELATED MACULAR DEGENERATION AND CANCER-ASSOCIATED PAIN

POTENTIAL OF DDRNAI TECHNOLOGY IS IMMENSE



Stuart Roberts, Baillieu Holst, May 2014

Thank you

Baillieu Holst

Since 1889

Stuart Roberts, Baillieu Holst, May 2014

KEEP LEARNING

- *Take a short online course*
- *Subscribe to the Investor Update e-newsletter*
- *Play the ASX Sharemarket Game*
- *Watch another ASX Investment video*

VISIT www.asx.com.au/education
#ASXvideo

ASX